HealthTree

Showing 94 trials matching your filters.

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Und...

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therap...

DRUG: Fludarabine

RADIATION: Total-Body Irradiation

PROCEDURE: Donor Lymphocyte Infusion

DRUG: Cyclophosphamide

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Melphalan

PROCEDURE: Bone Marrow Aspiration and Biopsy

PROCEDURE: Diagnostic Imaging

PROCEDURE: Biospecimen Collection

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, ...

DRUG: ELVN-001

Allo HSCT Using RIC and PTCy for Hematological Diseases

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem ce...

BIOLOGICAL: Peripheral Blood Stem Cell Transplant

DRUG: Allopurinol 300 MG

DRUG: Fludarabine

DRUG: Cyclophosphamide

BIOLOGICAL: Bone Marrow Cell Transplant

RADIATION: Total Body Irradiation

DRUG: Sirolimus Pill

DRUG: Mycophenolate Mofetil

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults...

This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from...

RADIATION: Total-Body Irradiation

DRUG: Thiotepa

DRUG: Fludarabine

DRUG: Cyclophosphamide

DRUG: Busulfan

PROCEDURE: Allogeneic Bone Marrow Transplantation

DRUG: Tacrolimus

DRUG: Methotrexate

PROCEDURE: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and M...

This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell transplant. Chemotherapy drug...

DRUG: Busulfan

DRUG: Cladribine

DRUG: Fludarabine Phosphate

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Thiotepa

DRUG: Venetoclax

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia ...

This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may ...

DRUG: Azacitidine

DRUG: Enasidenib Mesylate

Cord Blood Transplant in Adults With Blood Cancers

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the ...

DRUG: Conditioning Chemotherapy

BIOLOGICAL: Cord blood graft

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a s...

DRUG: APG-115

DRUG: 5-azacitidine

TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are in...

DRUG: TGRX-678

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission (TFR).

DRUG: Ruxolitinib

DRUG: BCR-ABL Tyrosine Kinase Inhibitor (TKI)

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination ...

DRUG: FHD-286

DRUG: Low Dose Cytarabine

DRUG: Decitabine

(Apex) Bezuclastinib in Patients with Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cel...

DRUG: bezuclastinib

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes n...

DRUG: Azacitidine

DRUG: Enasidenib

OTHER: Quality-of-Life Assessment

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatmen...

This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

DRUG: Cyclophosphamide

DRUG: Cyclosporine

BIOLOGICAL: Filgrastim

DRUG: Fludarabine

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Treosulfan

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Biospecimen Collection

PROCEDURE: Computed Tomography

PROCEDURE: Positron Emission Tomography

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelody...

This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia and Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap neoplasms that has come...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

DRUG: Onvansertib

PROCEDURE: Ultrasound Imaging

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.

DRUG: Talazoparib

DRUG: pacritinib

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Tra...

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it a...

DRUG: Busulfan

DRUG: Fludarabine

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

DRUG: Post-Transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient Reported Outcomes

DRUG: Melphalan

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell T...

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the gro...

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Cyclophosphamide

BIOLOGICAL: Cytokine-treated Veto Cells

DRUG: Fludarabine

PROCEDURE: Peripheral Blood Stem Cell Transplantation

RADIATION: Total-Body Irradiation

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclopho...

This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell trans...

DRUG: Busulfan

DRUG: Fludarabine

RADIATION: Total-body irradiation

DRUG: Cyclophosphamide

DRUG: Melphalan

PROCEDURE: PBSC Hematopoietic Stem Cell Transplantation (HSCT)

PROCEDURE: Bone Marrow Hematopoietic Stem Cell Transplantation

DRUG: Post-transplant Cyclophosphamide

DRUG: Mesna

DRUG: Tacrolimus

DRUG: Mycophenolate Mofetil

OTHER: Patient-Reported Outcomes

Study of Olverembatinib (HQP1351) in Patients With CP-CML

A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)

DRUG: olverembatinib

DRUG: Bosutinib

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also ...

DRUG: Itacitinib

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Pa...

This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Cytarabine

PROCEDURE: Echocardiography

DRUG: Fludarabine

DRUG: Hydrocortisone Sodium Succinate

BIOLOGICAL: Imetelstat

DRUG: Leucovorin Calcium

PROCEDURE: Lumbar Puncture

DRUG: Methotrexate

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutate...

This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in treating patients with FLT3-mutation positive acute myeloid leukemia, chronic myelomonocytic l...

DRUG: Azacitidine

DRUG: Gilteritinib

DRUG: Venetoclax

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloprolif...

This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syn...

BIOLOGICAL: Axatilimab

DRUG: Azacitidine

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration and Biopsy

OTHER: Survey Administration

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. I...

DRUG: Purified regulatory T-cells (Treg) plus CD34+ HSPC

DRUG: Fludarabine

DRUG: Melphalan

DEVICE: CliniMACS CD34 Reagent System

DRUG: Tacrolimus

DRUG: Cyclophosphamide

DRUG: Plerixafor

DRUG: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent

DRUG: Thiotepa

DRUG: Mycophenolate Mofetil (MMF)

DRUG: Ruxolitinib

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies o...

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combi...

DRUG: voruciclib monotherapy

DRUG: voruciclib and venetoclax

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Sy...

This phase I/II trial studies the side effects and best dose of venetoclax when given together with azacitidine in treating patients with high-risk myelodysplastic syndrome that has come back (recurrent) or does not respond to treatment (refractory)....

DRUG: Azacitidine

DRUG: Venetoclax

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase M...

This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors). Drugs used in chemoth...

DRUG: Decitabine

DRUG: Ruxolitinib

DRUG: Fedratinib

OTHER: Questionnaire Administration

DRUG: Pacritinib

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myelo...

This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product ca...

DRUG: Dasatinib

DRUG: Imatinib Mesylate

OTHER: Laboratory Biomarker Analysis

DRUG: Nilotinib

BIOLOGICAL: Pembrolizumab

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leuke...

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. F...

DRUG: Asciminib Pediatric formulation group

DRUG: Asciminib Adult formulation group

Personalized NK Cell Therapy in CBT

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This ...

BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92

BIOLOGICAL: Anti-Thymocyte Globulin

DRUG: Busulfan

DRUG: Clofarabine

DRUG: Cyclophosphamide

DRUG: Fludarabine Phosphate

OTHER: Laboratory Biomarker Analysis

DRUG: Melphalan

BIOLOGICAL: Rituximab

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Mye...

To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.

DRUG: Decitabine

DRUG: Listaftoclax

DRUG: Olverembatinib

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chron...

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chro...

DIETARY_SUPPLEMENT: Ascorbic Acid

DRUG: Carboplatin

DRUG: Cisplatin

DRUG: Cytarabine

DRUG: Dexamethasone

DRUG: Etoposide

DRUG: Gemcitabine Hydrochloride

DRUG: Ifosfamide

OTHER: Laboratory Biomarker Analysis

DRUG: Oxaliplatin

OTHER: Placebo Administration

OTHER: Questionnaire Administration

BIOLOGICAL: Rituximab

DRUG: Decitabine

PROCEDURE: Biospecimen Collection

PROCEDURE: Core Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Echocardiography

PROCEDURE: Positron Emission Tomography

PROCEDURE: Magnetic Resonance Imaging

PROCEDURE: Central Venous Cannula Insertion

PROCEDURE: Portacath Placement

PROCEDURE: Computed Tomography

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

Patients with medical conditions requiring allogeneic hematopoietic cell transplantation (allo-HCT) are at risk of developing a condition called graft versus host disease (GvHD) which carries a high morbidity and mortality. This is a phase I/II study...

DEVICE: CliniMACS

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

PROCEDURE: Haploidentical Bone Marrow/Kidney

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myel...

DRUG: ABL001

DRUG: Dasatinib

DRUG: Prednisone

DRUG: Blinatumomab

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, M...

This clinical trial involves individuals who have been diagnosed with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or MDS/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and...

DRUG: Venetoclax

DRUG: Fludarabine

DRUG: Busulfan

DRUG: Venetoclax

DRUG: Azacitidine

DRUG: Decitabine/cedazuridine

Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count,...

DRUG: Hyperbaric oxygen

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Dis...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

DRUG: Fludarabine

DRUG: Cyclophosphamide

RADIATION: Total Body Irradiation

DRUG: Cyclosporine A

DRUG: Mycophenylate mofetil

BIOLOGICAL: Umbilical cord blood

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose ...

DRUG: APG 2575 ramp up arm

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL0...

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kina...

DRUG: Asciminib 40 MG

DRUG: Asciminib 40 MG Twice Daily

DRUG: Asciminib 80 MG daily

DRUG: Imatinib

DRUG: Nilotinib

DRUG: Dasatinib

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patient...

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosp...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

DRUG: Cyclophosphamide

DRUG: Cyclosporine

PROCEDURE: Diagnostic Imaging

PROCEDURE: Echocardiography

DRUG: Fludarabine Phosphate

PROCEDURE: Multigated Acquisition Scan

DRUG: Mycophenolate Mofetil

OTHER: Survey Administration

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myelopr...

This phase I/II trial studies the side effects and best dose of quizartinib when given with azacitidine and to see how well they work in treating patients with myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasm with FLT3 or CBL m...

DRUG: Azacitidine

DRUG: Quizartinib

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MF and CMML (HSC...

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients will receive...

DRUG: Tagraxofusp

Ponatinib Hydrochloride As Second Line Therapy in Treating Patients with Chronic Myeloid Leukemia in...

This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, ...

OTHER: Laboratory Biomarker Analysis

DRUG: Ponatinib Hydrochloride

OTHER: Quality-of-Life Assessment

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World...

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.

OTHER: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal

DRUG: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malign...

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

BIOLOGICAL: OrcaGraft (Orca-Q)

Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

This is a first in children prospective study of allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q). The study will assess safety and efficacy of Orca-Q in pediatric patients with hematologic malig...

BIOLOGICAL: Orca-Q

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic...

This phase I/II trial identifies the best dose of seclidemstat when given together with azacitidine in treating patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Seclidemstat may stop the growth of cancer cells by blocking so...

DRUG: Azacitidine

DRUG: Seclidemstat

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With ...

This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase ...

DRUG: Bexmarilimab

DRUG: Azacitidine

DRUG: Venetoclax

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chron...

This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back ...

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Inqovi Maintenance Therapy in Myeloid Neoplasms

This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant. * This research study involve...

DRUG: Inqovi

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia,...

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as c...

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Gilteritinib

DRUG: Idarubicin

OTHER: Laboratory Biomarker Analysis

DRUG: Midostaurin

DRUG: Venetoclax

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to as...

DRUG: DFV890

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients Wit...

This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocyti...

DEVICE: Miltenyi CliniMACS Prodigy ® system

Selumetinib and Azacitidine in High Risk Chronic Blood Cancers

This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided ...

DRUG: Azacitidine

DRUG: Selumetinib

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplasti...

This phase I/II trial studies the side effects and best dose of venetoclax in combination with cedazuridine and decitabine (ASTX727) in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia who have not received...

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

Olutasidenib for the Treatment of Patients with IDH1 Mutated AML, MDS or CMML After Donor Hematopoie...

This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell transplant for acute myeloid leukemia (AML), myelo...

PROCEDURE: Biospecimen Collection

DRUG: Olutasidenib

KRT-232 and TKI Study in Chronic Myeloid Leukemia

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is ...

DRUG: KRT-232

DRUG: Dasatinib

DRUG: Nilotinib

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and...

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic an...

DRUG: EAGD T-cell infusion (Phase I)

DRUG: EAGD T-cell infusion (Expansion)

NTX-301 in MDS/AML

NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.

DRUG: NTX-301

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic M...

To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.

DRUG: Asciminib

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants...

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate t...

DRUG: PRT2527

DRUG: Zanubrutinib

DRUG: Venetoclax

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromos...

This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respo...

BIOLOGICAL: Blinatumomab

DRUG: Cytarabine

DRUG: Methotrexate

DRUG: Ponatinib

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy a...

DRUG: Asciminib

DRUG: Ascimininb + Nilotinib

DRUG: Asciminib + Imatinib

DRUG: Asciminib + Dasatinib

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Ch...

This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML. Specifically, the study will evaluate the safety and...

BIOLOGICAL: CD4CAR

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (B...

DRUG: Ascentage Pharma HQP1351 bioavailable inhibitor

DRUG: Blinatumomab

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Be...

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorecta...

DRUG: Vactosertib

DRUG: Fludarabine Phosphate

DRUG: Cyclophosphamide

DRUG: IL-2

DRUG: Natural Killer Cells

Asciminib Roll-over Study

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

DRUG: Asciminib single agent

DRUG: Imatinib

DRUG: Nilotinib

DRUG: Bosutinib

DRUG: Dasatinib

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Re...

This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back (relapsed) or that does not respond to treatmen...

DRUG: Gemtuzumab Ozogamicin

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

OTHER: Quality-of-Life Assessment

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.

DRUG: CFI-400945

DRUG: Azacitidine

Pacritinib in CMML

This is a phase 1/2 trial of pacritinib in combination with azacitidine in patients with Chronic Myelomonocytic Leukemia (CMML). Patients will be newly diagnosed or previously treated but could not have received a prior JAK inhibitor. Patients who ha...

DRUG: Pacritinib

DRUG: Azacitidine

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infect...

This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients ...

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

PROCEDURE: Biospecimen Collection

DRUG: Granulocyte Colony-Stimulating Factor

DRUG: Hematopoietic Cell Transplantation Conditioning Regimen

BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

PROCEDURE: Pheresis

DRUG: Placebo Administration

DRUG: Stem Cell Mobilization Therapy

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodyspla...

This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to l...

DRUG: Edetate Calcium Disodium

DIETARY_SUPPLEMENT: Multivitamin

DRUG: Succimer

Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia

This phase I/II trial studies the side effects, best dose, and effect of tagraxofusp and decitabine in treating patients with chronic myelomonocytic leukemia. Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3...

DRUG: Decitabine

BIOLOGICAL: Tagraxofusp-erzs

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion wi...

DEVICE: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MP...

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

DRUG: LP-118

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks f...

DRUG: Cobimetinib

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NP...

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

DRUG: BMF-219

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating W...

To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

DRUG: Cladribine

DRUG: Cytarabine

DRUG: Venetoclax

DRUG: Azacitidine

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematolo...

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory A...

DRUG: SLS009

DRUG: venetoclax

DRUG: azacitidine

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic ...

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies ...

DRUG: Darzalex Faspro (Daratumumab and hyaluronidase-fihj)

DEVICE: JH-DSA Semi-Quant Screen and Response Score

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

BIOLOGICAL: HSCT with TBI Regimen

BIOLOGICAL: HSCT with Non-TBI Regimen

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, ...

This phase II trial studies how well canakinumab works for the treatment of low- or intermediate-risk myelodysplastic syndrome or chronic myelomonocytic leukemia. Canakinumab is a monoclonal antibody that may interfere with the ability of cancer cell...

BIOLOGICAL: Canakinumab

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

The purpose of this study is to learn the effects of treatment with an investigational drug, CPX-351 in patients with secondary myeloid neoplasms (SMNs).

DRUG: CPX-351

DRUG: MHA

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Ma...

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

DRUG: EP31670

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies

This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation stu...

BIOLOGICAL: DSP107

DRUG: Azacitidine

DRUG: Venetoclax

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Othe...

This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplasti...

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Bone Marrow Biopsy

DRUG: Decitabine and Cedazuridine

DRUG: Venetoclax

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspet...

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 ...

DRUG: Tuspetinib

DRUG: Venetoclax Oral Tablet

DRUG: Azacitidine for Intravenous Infusion

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Stud...

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collec...

DRUG: decitabine

DRUG: spartalizumab

DRUG: sabatolimab

DRUG: azacitidine

DRUG: venetoclax

DRUG: INQOVI (oral decitabine)

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positi...

This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are...

DRUG: Dasatinib

DRUG: Decitabine and Cedazuridine

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for th...

This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy reduced-intensity condition...

DRUG: Cladribine

DRUG: Cyclophosphamide

DRUG: Cyclosporine

DRUG: Cytarabine

BIOLOGICAL: Filgrastim

PROCEDURE: Hematopoietic Cell Transplantation

DRUG: Mitoxantrone

DRUG: Mycophenolate Mofetil

DRUG: Mycophenolate Sodium

RADIATION: Total-Body Irradiation

DRUG: Idarubicin

DRUG: Fludarabine

DRUG: Cytarabine

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Echocardiography

PROCEDURE: X-Ray Imaging

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Bone Marrow Aspiration

PROCEDURE: Biospecimen Collection

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patien...

This phase II trial studies how well donor umbilical cord blood transplant with ex-vivo expanded cord blood progenitor cells (dilanubicel) works in treating patients with blood cancer. Before the transplant, patients will receive chemotherapy (fludar...

BIOLOGICAL: Dilanubicel

DRUG: Cyclophosphamide

DRUG: Fludarabine

DRUG: Thiotepa

RADIATION: Total-Body Irradiation

PROCEDURE: Umbilical Cord Blood Transplantation

OTHER: Laboratory Biomarker Analysis

PROCEDURE: Biospecimen Collection

PROCEDURE: Bone Marrow Aspirate

PROCEDURE: Bone Marrow Biopsy

PROCEDURE: Multigated Acquisition Scan

PROCEDURE: Electrocardiography

PROCEDURE: Computed Tomography

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed t...

DRUG: MGD024

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Your Source for Expert Insights & Support in Chronic Myeloid Leukemia.

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info